PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31093950-1	2019	Peficitinib [Smyraf  (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis.	peficitinib	0-11	Janus kinase 3	Homo sapiens	72-76	
31059310-6	2019	Expert opinion: Peficitinib is a novel JAK3 inhibitor potently inhibiting JAK3 enzymatic activity and JAK1/3-mediated cell proliferation.	peficitinib	16-27	Janus kinase 3	Homo sapiens	39-43	
31059310-0	2019	JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.	peficitinib	25-36	Janus kinase 3	Homo sapiens	0-4	
31059310-6	2019	Expert opinion: Peficitinib is a novel JAK3 inhibitor potently inhibiting JAK3 enzymatic activity and JAK1/3-mediated cell proliferation.	peficitinib	16-27	Janus kinase 3	Homo sapiens	74-78	
30145050-5	2018	Furthermore, we determined the crystal structures of JAK1, JAK2, JAK3, and TYK2 in a complex with peficitinib, and revealed that the 1H-pyrrolo[2,3-b]pyridine-5-carboxamide scaffold of peficitinib forms triple hydrogen bonds with the hinge region.	peficitinib	98-109	Janus kinase 3	Homo sapiens	65-69	
30145050-6	2018	Interestingly, the binding modes of peficitinib in the ATP-binding pockets differed among JAK1, JAK2, JAK3, and TYK2.	peficitinib	36-47	Janus kinase 3	Homo sapiens	102-106	
30145050-3	2018	Here, we describe the identification of the novel orally bioavailable JAK inhibitor 18, peficitinib (also known as ASP015K), which showed moderate selectivity for JAK3 over JAK1, JAK2, and TYK2 in enzyme assays.	peficitinib	88-99	Janus kinase 3	Homo sapiens	163-167